Lobbying Relationship

Client

Momenta Pharmaceuticals, Inc.

More records

Lobbying firm

Jennings Policy Strategies

More records

  • Advocate for biopharmaceutical cost containment policies aimed at creating a workable, science-based regulatory pathway for access to affordable generic biologic medications (including but not limited to H.R. 1427, S. 726 and H.R. 1548)

Duration: to

General Issues: Health Issues, Pharmacy, Insurance

Spending: about $260,000 (But it's complicated. Here's why.)

Agencies lobbied since 2007: House of Representatives, U.S. Senate, Office of Management & Budget (OMB), White House Office, U.S. Senate,, Congressional Budget Office (CBO), Y Y

Bills mentioned

H.R.1427: Promoting Innovation and Access to Life-Saving Medicine Act

Sponsor: Henry A. Waxman (D-Calif.)

S.726: Promoting Innovation and Access to Life-Saving Medicine Act

Sponsor: Charles E. Schumer (D-N.Y.)

H.R.1548: Pathway for Biosimilars Act

Sponsor: Anna G. Eshoo (D-Calif.)

H.R.1038: Access to Life-Saving Medicine Act

Sponsor: Henry A. Waxman (D-Calif.)

S.623: Access to Life-Saving Medicine Act

Sponsor: Charles E. Schumer (D-N.Y.)

H.R.5629: Pathway for Biosimilars Act

Sponsor: Anna G. Eshoo (D-Calif.)

H.R.1956: Patient Protection and Innovative Biologic Medicines Act of 2007

Sponsor: Jay Inslee (D-Wash.)

S.1505: Affordable Biologics for Consumers Act

Sponsor: Judd Gregg (R-N.H.)

S.1695: Biologics Price Competition and Innovation Act of 2007

Sponsor: Edward M. Kennedy (D-Mass.)

Show All Mentioned Bills

Lobbyists

Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.

Lobbyist Covered positions?
KATHERINE HAYES HEALTH COUNSEL, US SENATOR EVAN BAYH Health Counsel, U.S. Senator Evan Bayh
Christopher Jennings n/a

Disclosures Filed

Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.

Q2 Report
Termination
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Q1 Report
MM Report

Source: Clerk of the U.S. House of Representatives and Secretary of the Senate

Close Comment Creative Commons Donate Email Facebook Mobile Phone Podcast Print Google News logo Google_NewsInitiative_Lockup_FullColor RSS Search Search Twitter WhatsApp Resolving differences Check Building Arrow right Info circle Oops OOPS Pencil File text Bars Search Close Cogs Filter Compare Revolving Door Info card Activity Member menu Globe Document External link Quote News Calendar No Vote
Current site Current page